By Alex Kiselyov, CEO, Myocea, Inc. Myocea is a biotechnology startup with a focus on neuromuscular disorders. Our product pipeline is championed by the small molecule GBC0905 (Rebastinib) aimed at… Read More »
New biotech is developing Genea Biocells’ FSHD drug
More than a pretty pair of shoes
by Barbara Zehetbauer-Hoehl, Vienna, Austria Three years ago, I developed a symptom called foot drop caused by my FSHD Type 2. The biggest loss, which came with losing my muscles… Read More »
COVID-19 Vaccine Q&A
This Q&A is based on the December 9 webinar with Rabi Tawil, MD, and Ghinwa Dumyati, MD, from the University of Rochester Medical Center, and the January 15 webinar hosted… Read More »
MRI in FSH muscular dystrophy research
This month’s FSHD University webinar (video above) provided an outstanding, nontechnical explanation of magnetic resonance technology (MRI) and how it is being applied in the Fulcrum Therapeutics clinical trial… Read More »
Legacy planning made simpler
If you have ever wished that you could do more to help in the fight against FSHD, we invite you to consider joining the FSHD Society Legacy Circle by including… Read More »